Treatment and survival for patients with localized primary ocular adnexal extranodal marginal zone lymphoma
Lin-Rui Gao,Xin Li,Xinyue Wang,Yuanzheng Liang,Yunpeng Wu,Xiao-Li Feng,Wei Rao,Xin Liu,Yong-Wen Song,Hui Fang,Bo Chen,Jing Jin,Yue-Ping Liu,Hao Jing,Yuan Tang,Ning-Ning Lu,Shu-Lian Wang,Ye-Xiong Li,Liang Wang,Shu-Nan Qi
DOI: https://doi.org/10.1038/s41375-024-02227-5
2024-03-21
Leukemia
Abstract:Primary ocular adnexal extranodal marginal zone lymphoma (OA-EMZL) represents the second most common EMZL [1,2,3] and the predominant type of ocular adnexal lymphoma [4], with a favorable prognosis and an excellent 5-year overall survival (OS) rate ( > 95%) [3]. Guidelines recommend radical radiotherapy (RT) as the standard of care for localized OA-EMZL [5, 6]. In real-world practice, early-stage lesions are diversely managed with RT, observation, chemotherapy, immunotherapy, and/or surgical resection, depending on the age and performance status (PS) of the patient, the disease extent, and other clinical factors [4, 7]. In the past two decades, a significant trend toward omission of RT for early-stage EMZL has been recorded [2, 8], probably because of concerns regarding long-term toxicity [2]. This trend has been particularly prominent in China, and data regarding EMZL are notably scarce. However, analysis of the association between treatment and survival in a large dataset showed results favoring primary RT over no RT, with a >10% difference in both OS and relative survival (RS) [2]. Moreover, data on long-term toxicities and quality of life (QoL) after different treatments are limited [9,10,11]. More data regarding progression, survival, and impact on QoL based on specific sites and long-term follow-up are needed to optimize the management of EMZL. In this study, data for patients with histologically diagnosed, stage IE OA-EMZL between January 2000 and December 2020 were retrospectively reviewed at Cancer Hospital of Chinese Academy of Medical Sciences (a specialized cancer hospital) and Beijing TongRen Hospital (a comprehensive hospital specializing in ophthalmology). The Supplementary Methods show the inclusion criteria. In total, 262 patients were recruited. The baseline characteristics are summarized in Table S1, while the previous medical histories and anatomical locations are summarized in Table S2. Briefly, the median age was 55 years, 60 patients (22.9%) had bilateral lesions, and 84 patients (32.1%) showed tumors at multiple sites within the ocular adnexa.
oncology,hematology